Public Sector Pension Investment Board increased its position in Ralliant Corporation (NYSE:RAL – Free Report) by 14.4% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 439,714 shares of the company’s stock after purchasing an additional 55,237 shares during the period. Public Sector Pension Investment Board owned 0.39% of Ralliant worth $19,229,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Aberdeen Group plc acquired a new stake in Ralliant during the second quarter valued at approximately $5,042,000. CWM LLC bought a new stake in shares of Ralliant in the 2nd quarter valued at approximately $280,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Ralliant during the 2nd quarter valued at approximately $281,000. Yousif Capital Management LLC bought a new position in Ralliant during the second quarter worth $2,826,000. Finally, TD Asset Management Inc bought a new position in Ralliant during the second quarter worth $13,190,000.
Ralliant Stock Up 3.4%
Shares of Ralliant stock opened at $44.03 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $57.02. The business’s fifty day moving average price is $50.79 and its two-hundred day moving average price is $46.56. The company has a market capitalization of $4.97 billion and a P/E ratio of 22.46.
Ralliant Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, March 9th. Ralliant’s payout ratio is 10.20%.
Analyst Upgrades and Downgrades
Several analysts have weighed in on RAL shares. Zacks Research lowered shares of Ralliant from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Friday, February 6th. Barclays cut their target price on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Royal Bank Of Canada decreased their target price on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 6th. Finally, Truist Financial dropped their price target on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $50.50.
Read Our Latest Stock Analysis on Ralliant
Ralliant News Summary
Here are the key news stories impacting Ralliant this week:
- Positive Sentiment: Directors/insiders bought stock this week (Kate Mitchell bought 2,350 shares at ~$42.48; Anelise Angelino Sacks bought ~2,000 shares), a signal often read as confidence in the company and a near‑term support for the share price. InsiderTrades: Kate Mitchell Acquires 2,350 Shares The Motley Fool: Director Scoops Up 2,000 Shares
- Neutral Sentiment: Recent quarterly results beat consensus (EPS and revenue) and the company provided Q1 and FY 2026 guidance — fundamentals remain mixed and will be watched closely but are not a new surprise. MarketBeat: Ralliant Earnings & Guidance
- Negative Sentiment: Multiple law firms have publicly opened or promoted investigations into possible securities‑law violations tied to Ralliant (Kaplan Fox, Kirby McInerney, Kessler Topaz, Block & Leviton and others). Those actions increase litigation and regulatory risk and can pressure the stock as legal costs, disclosures and management distraction unfold. Globe and Mail: Kaplan Fox Alert GlobeNewswire: Kirby McInerney Alert
- Negative Sentiment: Ongoing negative analyst moves, higher short interest and prior material non‑cash impairment/guidance reductions (reported earlier) raise downside risk and intraday volatility — these factors can offset positive insider signals and lead to further selling on adverse updates. Kessler Topaz PR Business Insider: Block & Leviton Alert
Insider Activity at Ralliant
In other news, Director Kevin E. Bryant bought 1,250 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were purchased at an average price of $39.97 per share, with a total value of $49,962.50. Following the completion of the acquisition, the director directly owned 4,653 shares in the company, valued at approximately $185,980.41. This trade represents a 36.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kate Mitchell bought 2,350 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was purchased at an average price of $42.48 per share, with a total value of $99,828.00. Following the completion of the transaction, the director directly owned 8,411 shares of the company’s stock, valued at $357,299.28. This trade represents a 38.77% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 8,145 shares of company stock valued at $332,233 over the last quarter.
About Ralliant
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Read More
- Five stocks we like better than Ralliant
- ALERT: Drop these 5 stocks before January 2026!
- Buy This Stock Now
- Trump Planning to Use Public Law 63-43: Prepare Now
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Your Bank Account Is No Longer Safe
Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL – Free Report).
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
